Table 2: Final meta analysis.

Identifying data

Summary data

Source

Year

Significant cancer definition

Detection rate any cancer, SB (%)

Detection rate clinically significant cancer, SB (%)

Patients with clinically significant cancer detected by SB only (Missed by Tbx) (%)

Patients with clinically insignificant cancer detected by SB only (Missed by Tbx) (%)

Detection rate any cancer, TB (%)

Detection rate clinically significant cancer, TB (%)

Patients with clinically significant cancer detected by TB only (Missed by SB) (%)

Da Rosa, et al.

2014

Epstein

29.2

16.7

10.53

25.00

36.11

23.61

36.84

Fiard, et al.

2013

Cancer volume ≥ 0.5 mL, pathological stage ≥ pT3 or Gleason ≥ 3 + 4

43.3

33.3

9.09

66.67

36.67

33.33

9.09

Haffner, et al.

2010

Epstein

52.3

42.7

5.22

100.00

42.52

42.52

4.82

Hu, et al.

2014

Gleason ≥ 3 + 4

58.9

20.0

47.83

46.34

37.78

13.33

21.74

Kasivisvanathan, et al.

2013

Cancer core length ≥ 4 mm or Gleason ≥ 3 + 4

79.1

62.1

20.77

63.64

65.93

56.59

13.08

Lawrence, et al.

2014

Gleason ≥ 3 + 4

30.8

12.8

0.00

57.14

30.77

23.08

44.44

Mozer, et al.

2014

Cancer core length ≥ 4 mm or Gleason ≥ 3 + 4

56.6

36.8

5.71

33.33

53.95

43.42

20.00

*Park, et al.

2011

Gleason ≥ 3 + 3

27.3

27.3

30.77

N/A

20.45

20.45

7.69

Pepe, et al.

2013

Gleason ≥ 3 + 3

35.9

35.9

18.75

N/A

33.33

33.33

12.50

Pokorny, et al.

2014

NR

56.5

35.4

13.89

82.35

44.39

41.70

26.85

Puech, et al.

2013

Cancer core length ≥ 3 mm or Gleason ≥ 3 + 4

58.9

51.6

1.54

71.43

69.47

67.37

24.62

Quentin, et al.

2014

Gleason ≥ 3 + 4

53.1

42.2

9.38

28.57

53.13

45.31

15.63

Radtke, et al.

2014

Gleason ≥ 3 + 4

65.8

34.7

12.79

43.75

56.63

38.27

20.93

Salami, et al.

2014

Epstein

48.6

30.7

6.94

68.42

52.14

47.86

40.28

Shakir, et al.

2014

Gleason ≥ 3 + 4

46.8

12.2

9.90

22.58

45.96

17.25

36.46

Somford, et al.

2013

Gleason ≥ 3 + 3

100.0

100.0

0.00

51.06

53.70

11.11

0.00

Sonn, et al.

2013

Epstein

26.6

13.8

13.64

77.78

22.34

20.21

40.91

Wysock, et al.

2014

Gleason ≥ 3 + 4

55.2

32.8

12.00

64.29

40.30

32.84

12.00

 

*(targeted was not performed in two pts bc systematic covered suspected cancer).